Skip to main content

Table 1 Correlation between CDCA3 expression and clinical classification in OSCCs

From: Overexpression of cell cycle regulator CDCA3 promotes oral cancer progression by enhancing cell proliferation with prevention of G1 phase arrest

  

Results of immunostaining

 

Clinical classification

 

No. patients (%)

 
 

Total

CDCA3 negative

CDCA3 positive

pvalue

Age at surgery (years)

    

<60

23

9 (39)

14 (61)

 

60, <70

22

11 (50)

11 (50)

0.852

70

50

22 (44)

28 (56)

 

Gender

    

Male

58

28 (48)

30 (52)

0.317

Female

37

14 (38)

23 (62)

 

T-primary tumor

    

T1

6

3 (50)

3 (50)

0.020*

T2

56

30 (54)

26 (46)

 

T3

15

5 (33)

10 (67)

 

T4

18

4 (22)

14 (78)

 

T1 + T2

62

33 (53)

29 (47)

0.015*

T3 + T4

33

9 (27)

24 (73)

 

N-regional lymph node

    

N (−)

56

25 (45)

31 (55)

0.919

N (+)

39

17 (44)

22 (56)

 

Stage

    

I

6

3 (50)

3 (50)

0.235

II

36

18 (50)

18 (50)

 

III

17

8 (47)

9 (53)

 

IV

36

13 (36)

23 (64)

 

Histopathologic type

    

Well

60

26 (43)

34 (57)

0.803

Moderately

31

14 (45)

17 (55)

 

Poorly

4

2 (50)

2 (50)

 

Tumor site

    

Gingiva

28

9 (32)

19 (68)

0.456

Tongue

51

25 (49)

26 (51)

 

Buccal mucosa

9

4 (44)

5 (56)

 

Oral floor

7

4 (57)

3 (43)

 
  1. *p < 0.05.